EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING

Yoo Sun Kim, Barzin Y Nabet, Briana N Cortez, Nai-Yun Sun, Robin Sebastian, Christophe E Redon, Anagh Ray, Liang Liu, Afeez A Ishola, Sarah Loew, Anjali Dhall, Sivasish Sindiri und 19 weitere

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci185423 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Yoo Sun Kim und 30 weiteren Autor:innen. Beteiligte Einrichtung: Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Receptor, Notch1, Lung Neoplasms, Membrane Proteins. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH Intramural Program, Taiho Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Downregulation of antigen presentation and lack of immune infiltration are defining features of small cell lung cancer (SCLC), limiting response to immune checkpoint blockade (ICB). While a high–MHC class I, immune-inflamed subset benefits from ICB, underlying mechanisms of immune response in SCLC have yet to be elucidated. Here we show that in the IMpower133 clinical trial, high, but not low, NOTCH1 expression was significantly associated with longer survival with the addition of ICB to chemotherapy among approximately 80% of SCLC patients with NE-enriched tumors ( ASCL1 -enriched, HR 0.39, P = 0.0012; NEUROD1 -enriched, HR 0.44, P = 0.024). Overexpression or pharmacologic activation of NOTCH1 in ASCL1 and NEUROD1 SCLC cell lines dramatically upregulated MHC class I through epigenetic reactivation of STING. In syngeneic mouse models, Notch1 activation reprogrammed SCLC tumors from immune-excluded to immune-inflamed, facilitating durable, complete responses with ICB combined with a STING agonist. STING1 expression was significantly enriched in high- compared with low- NOTCH1- expressing tumors in IMpower133, validating our proposed mechanism. Our data reveal a previously undiscovered role for NOTCH1 as a critical driver of SCLC immunogenicity and a potential predictive biomarker for ICB in SCLC. NOTCH1 activation may be a therapeutic strategy to unleash antitumor immune responses in SCLC and other neuroendocrine cancers in which NOTCH1 is typically suppressed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaReceptor, Notch1Lung NeoplasmsMembrane ProteinsNeoplasm ProteinsAnimalsHumansMiceCell Line, TumorFemaleMaleSTING Protein

Stichwörter der Autor:innen

AntigenBiomarkersCancer immunotherapyCell biologyImmunologyOncology

Substanzen

Receptor, Notch1Membrane ProteinsNeoplasm ProteinsNOTCH1 protein, humanSTING1 protein, humanSTING ProteinSting1 protein, mouseNotch1 protein, mouse

Autor:innen und Institutionen

  • Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
  • Genentech Inc., South San Francisco, California, USA.
  • Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
  • Rancho Biosciences, San Diego, California, USA.
  • Collaborative Protein Technology Resource, Center for Cancer Research, and.
  • Protein Characterization Laboratory, National Cancer Institute, Bethesda, Maryland, USA.

Förderung

  • NIH Intramural Program
  • Taiho Pharmaceutical

Zitieren

APA

Kim, Y. S., Nabet, B. Y., Cortez, B. N., Sun, N. Y., Sebastian, R., Redon, C. E., Ray, A., Liu, L., Ishola, A. A., Loew, S., Dhall, A., Sindiri, S., Gayevskiy, V., Lee, M. J., Rastogi, S., Sato, N., Kedei, N., Andresson, T., Das, S., …, & Roper, N. (2025). NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING. Journal of Clinical Investigation. https://doi.org/10.1172/jci185423

Vancouver

Kim YS, Nabet BY, Cortez BN, Sun NY, Sebastian R, Redon CE, et al. NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING. Journal of Clinical Investigation. 2025. doi:10.1172/jci185423

BibTeX
@article{Kim2025,
  author = {Kim, Yoo Sun and Nabet, Barzin Y and Cortez, Briana N and Sun, Nai-Yun and Sebastian, Robin and Redon, Christophe E and Ray, Anagh and Liu, Liang and Ishola, Afeez A and Loew, Sarah and Dhall, Anjali and Sindiri, Sivasish and Gayevskiy, Velimir and Lee, Min-Jung and Rastogi, Shraddha and Sato, Nahoko and Kedei, Noemi and Andresson, Thorkell and Das, Sudipto and Kumar, Suresh and Bers, Alan E and Zhang, Hongliang and Chiappori, Alberto and Gopal, Priyanka and Abazeed, Mohamed E and Chen, Haobin and Aladjem, Mirit I and Pommier, Yves and Velez, Moises J and Shames, David S and Roper, Nitin},
  title = {NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci185423}
}
Kostenlos starten →